This trial is active, not recruiting.

Condition pick disease of the brain
Treatment radiation: far infrared radiation (5μm to 20μm wavelength)
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date May 2008
End date May 2009
Trial size 0 participants
Trial identifier NCT00674960, GAAD-FD-CTP1


Pick's disease, also known as Pick disease,or FTD is a rare fronto-temporal neurodegenerative disease. This study will investigate the use of far infrared radiation for the control, management and treatment of Pick's disease.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
radiation: far infrared radiation (5μm to 20μm wavelength) Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Primary Outcomes

Therapy for FTD patients
time frame: 1 year

Secondary Outcomes

Rehabilitation of FTD Patients
time frame: 1 Year

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - People with Pick's Disease Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Management, Control and Treatment of Frontotemporal Dementia (Pick's Disease)
Principal investigator Ken Nedd, M.D.
Description This disorder causes progressive destruction of nerve cells in the brain and causes tau proteins to accumulate into the "Pick bodies" that are a defining characteristic of the disease. Tau proteins are microtubule-associated proteins that are abundant in neurons in the central nervous system and are less common elsewhere. Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have FTD.
Trial information was received from ClinicalTrials.gov and was last updated in August 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..